Trial Profile
BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Adalimumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMvent
- Sponsors AbbVie; Boehringer Ingelheim Pharma KG
- 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023
- 01 Nov 2022 Results of post hoc analysis of three studies(N = 53,IMMvent NCT02694523, N = 172, UltIMMa-1 NCT02684370and UltIMMa-2 NCT02684357) assessing Psoriasis Area Severity Index and Dermatology Life Quality Index results from patients who switched to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients published in the Journal of Dermatological Treatment
- 25 Apr 2021 Results (n=2,109) of pooled analysis from three phase 3 trials ((NCT02684370, NCT02684357, NCT02694523) evaluating the impact of risankizumab withdrawal on HRQL measured by the Dermatology Life Quality Index (DLQI) presented at the American Academy of Dermatology Virtual Meeting Experience 2021